-
United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA
•
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing for a biosimilar version of Novo Nordisk’s (NYSE: NVO) weight loss drug semaglutide (Ozempic/Wegovy) has been accepted for review by China’s National Medical Products Administration (NMPA). This marks a significant step towards introducing a more…
-
Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million
•
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is poised to conduct an initial public offering (IPO) of 45,398,800 shares on the Hong Kong Stock Exchange (HKEX) on November 26, following the receipt of approval from the exchange earlier this week. The company has priced each share at 12.56, aiming to raise…
-
Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments
•
Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing hearing by The Stock Exchange of Hong Kong Limited for its initial public offering (IPO). While the price and other key details have not been disclosed at this stage, the company’s listing marks a significant…
